JP5520228B2 - 水溶解度の低い治療剤のナノ粒子 - Google Patents

水溶解度の低い治療剤のナノ粒子 Download PDF

Info

Publication number
JP5520228B2
JP5520228B2 JP2010535434A JP2010535434A JP5520228B2 JP 5520228 B2 JP5520228 B2 JP 5520228B2 JP 2010535434 A JP2010535434 A JP 2010535434A JP 2010535434 A JP2010535434 A JP 2010535434A JP 5520228 B2 JP5520228 B2 JP 5520228B2
Authority
JP
Japan
Prior art keywords
nanoparticles
derivative
active agent
paclitaxel
squalene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010535434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506276A (ja
JP2011506276A5 (OSRAM
Inventor
クーブレイ，パトリック
ラッキレディー，アリヴァーダン，レディー
ドシオ，フランコ
ステッラ，バーバラ
カッテル，ルイジ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2011506276A publication Critical patent/JP2011506276A/ja
Publication of JP2011506276A5 publication Critical patent/JP2011506276A5/ja
Application granted granted Critical
Publication of JP5520228B2 publication Critical patent/JP5520228B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2010535434A 2007-11-27 2008-11-27 水溶解度の低い治療剤のナノ粒子 Active JP5520228B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0708296 2007-11-27
FR0708296A FR2924024B1 (fr) 2007-11-27 2007-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
PCT/FR2008/052147 WO2009071850A2 (fr) 2007-11-27 2008-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse

Publications (3)

Publication Number Publication Date
JP2011506276A JP2011506276A (ja) 2011-03-03
JP2011506276A5 JP2011506276A5 (OSRAM) 2012-01-19
JP5520228B2 true JP5520228B2 (ja) 2014-06-11

Family

ID=39521786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010535434A Active JP5520228B2 (ja) 2007-11-27 2008-11-27 水溶解度の低い治療剤のナノ粒子

Country Status (7)

Country Link
US (1) US8962552B2 (OSRAM)
EP (1) EP2219678B1 (OSRAM)
JP (1) JP5520228B2 (OSRAM)
CN (1) CN101925365B (OSRAM)
CA (1) CA2706933C (OSRAM)
FR (1) FR2924024B1 (OSRAM)
WO (1) WO2009071850A2 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2937537A1 (fr) 2008-10-29 2010-04-30 Centre Nat Rech Scient Nanoparticules de statine
WO2010050624A1 (en) * 2008-10-31 2010-05-06 Hitachi Koki Co., Ltd. Centrifuge
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
FR2988092B1 (fr) 2012-03-16 2014-04-25 Centre Nat Rech Scient Complexes de vitamine c, nanoparticules desdits complexes, procedes pour leur preparation, leurs compositions, leurs utilisations cosmetiques et procede de traitement cosmetique
RU2664700C2 (ru) 2012-05-10 2018-08-21 Пейнреформ Лтд. Депо-составы местного анестетика и способы их получения
CN103421085B (zh) * 2012-05-18 2015-07-29 中国科学院上海药物研究所 用于增加紫杉醇或以紫杉醇结构为基础的类似药物的溶解度的寡肽
CN103351424B (zh) * 2013-06-09 2016-05-04 东南大学 一种紫杉醇或多烯紫杉醇奥曲肽偶联物的制备方法
KR102008859B1 (ko) * 2014-10-06 2019-08-08 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 담체-항체 조성물 및 그의 제조 및 사용 방법
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
JP6769976B2 (ja) 2015-10-07 2020-10-14 大日本住友製薬株式会社 ピリミジン化合物
TW202011986A (zh) 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物
EP3598982A1 (en) * 2018-07-23 2020-01-29 Centre National De La Recherche Scientifique Bioconjugates of neuropeptides derivatives
FR3110427B1 (fr) 2020-05-20 2023-07-14 Laboratoires Eriger Conjugué terpenique de couplage
WO2024131737A1 (zh) * 2022-12-19 2024-06-27 元樟生物科技股份有限公司 药物连接子及连接子共轭化合物
CN119613473A (zh) * 2024-12-06 2025-03-14 大连医科大学 阿霉素-角鲨烯小分子前药及其制备方法和应用
CN120210296A (zh) * 2025-03-27 2025-06-27 安徽天寅生物技术有限公司 一种纳米级水溶性角鲨烯的制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02204489A (ja) * 1989-02-02 1990-08-14 Ajinomoto Co Inc 易溶性２’，３’―ジデオキシイノシン、その製造法及び２’，３’―ジデオキシイノシン水性溶液の製造法
US5489589A (en) * 1994-12-07 1996-02-06 Bristol-Myers Squibb Company Amino acid derivatives of paclitaxel
GB9718791D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Medicaments
HK1045646A1 (zh) * 1999-05-21 2002-12-06 Abraxis Bioscience, Llc 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
US20050100577A1 (en) * 2003-11-10 2005-05-12 Parker Theodore L. Expandable medical device with beneficial agent matrix formed by a multi solvent system
FR2874016B1 (fr) 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse Nanoparticules de derives de la gemcitabine
US20060198940A1 (en) * 2005-03-04 2006-09-07 Mcmorrow David Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance

Also Published As

Publication number Publication date
CN101925365B (zh) 2013-03-06
FR2924024B1 (fr) 2012-08-17
JP2011506276A (ja) 2011-03-03
WO2009071850A2 (fr) 2009-06-11
CN101925365A (zh) 2010-12-22
EP2219678A2 (fr) 2010-08-25
WO2009071850A8 (fr) 2009-09-17
FR2924024A1 (fr) 2009-05-29
EP2219678B1 (fr) 2021-05-19
US8962552B2 (en) 2015-02-24
US20100305030A1 (en) 2010-12-02
CA2706933A1 (fr) 2009-06-11
WO2009071850A3 (fr) 2009-11-26
CA2706933C (fr) 2016-07-05

Similar Documents

Publication Publication Date Title
JP5520228B2 (ja) 水溶解度の低い治療剤のナノ粒子
Shi et al. RGD peptide-decorated micelles assembled from polymer–paclitaxel conjugates towards gastric cancer therapy
Tang et al. Design, preparation and evaluation of different branched biotin modified liposomes for targeting breast cancer
US6380405B1 (en) Taxane prodrugs
US9533054B2 (en) Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof
Li et al. Effective deactivation of A549 tumor cells in vitro and in vivo by RGD-decorated chitosan-functionalized single-walled carbon nanotube loading docetaxel
CZ2002928A3 (cs) Taxanová proléčiva
US20210228530A1 (en) Taxane-lipid-polysaccharide dual conjugates, preparation methods thereof and uses thereof
JP2007509978A (ja) トコフェロール修飾治療薬化合物
CN108478803A (zh) 氧化还原超敏感二硫键桥连前药自组装纳米粒的构建
CN106581693B (zh) 一种具有抗癌活性的熊果酸偶联物作为药物载体或者分子探针载体的应用
WO2011066418A1 (en) The tumor-selective anti-cancer prodrug bqc-g
CN111484501A (zh) 羟基喜树碱亚油酸酯小分子前药及其自组装纳米粒的构建
CN107335060A (zh) 一类基于rgd多肽-化疗药物的小分子偶联物及其纳米前药系统
CN113264906B (zh) 多西他赛二聚体小分子前药及其自组装纳米粒的构建
JP2004529116A (ja) タキサンプロドラッグ
CN108670954B (zh) 一种共载化疗药物的甘草次酸前药胶束及其制备方法
CN104368011A (zh) 一种药物甜菜碱缀合物、其药物组合物及应用
Zhang et al. Rational engineering of cholesterol-modified prodrug nanoassemblies for improving the tumor selectivity and safety of mitoxantrone
Wang et al. ‘Prodrug-Like’acetylmannosamine modified liposomes loaded with arsenic trioxide for the treatment of orthotopic glioma in mice
CN1875022B (zh) 生育酚修饰的治疗性药物化合物
CN110237255B (zh) 靶向肿瘤细胞的给药体系及其制备方法及应用
CN112891552A (zh) 一种靶向肝细胞癌的紫杉醇半乳糖胺缀合物、纳米粒及其制备方法和应用
CN113398276B (zh) 脑胶质瘤靶向小檗碱与叶酸修饰的脂质材料的制备与应用
US11464864B2 (en) Drug-bound compound and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140404

R150 Certificate of patent or registration of utility model

Ref document number: 5520228

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250